Showing results (501-510 of 523) with videos related to
Sort By:
Pageof 53
The British Journal of Dermatology|July 3, 2026
Durability of Response to Icotrokinra in Adults With Moderate-to-Severe Plaque Psoriasis: One-Year Results From the Phase 3, Placebo- and Active Comparator-Controlled ICONIC-ADVANCE 1 & ICONIC-ADVANCE 2 TrialsLinda Stein Gold, April W Armstrong, Jennifer Soung, et al.Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|October 8, 2021
Documentation of psoriasis in routine care - expert consensus on a German data setMarina Otten, Ulrich Mrowietz, Ralph Michael von Kiedrowski, et al.Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|July 11, 2007
Evidence-based (S3) guidelines for the treatment of psoriasis vulgarisAlexander Nast, Ina B Kopp, Matthias Augustin, et al.Allergy|April 9, 2023
Dupilumab but not cyclosporine treatment shifts the microbiome toward a healthy skin flora in patients with moderate-to-severe atopic dermatitisJan Hartmann, Lucas Moitinho-Silva, Nicole Sander, et al.Journal of the European Academy of Dermatology and Venereology : JEADV|October 13, 2025
Safety and efficacy of nemolizumab for atopic dermatitis up to 2 years in open-label extension studyMatthias Augustin, Marie Tauber, Robert Sidbury, et al.Journal of the European Academy of Dermatology and Venereology : JEADV|October 19, 2022
Quality of life measurement in vitiligo. Position statement of the European Academy of Dermatology and Venereology Task Force on Quality of Life and Patient Oriented Outcomes with external expertsPavel V Chernyshov, Lucia Tomas-Aragones, Liana Manolache, et al.Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|February 5, 2026
S3 Guideline for the Treatment of Psoriasis vulgaris, adapted from EuroGuiDerm - part 2: Specific clinical and comorbid situationsAlexander Nast, Andreas Altenburg, Matthias Augustin, et al.JAMA Dermatology|November 27, 2024
Efficacy and Safety of Nemolizumab in Patients With Moderate to Severe Prurigo Nodularis: The OLYMPIA 1 Randomized Clinical Phase 3 TrialSonja Ständer, Gil Yosipovitch, Franz J Legat, et al.Acta Dermato-Venereologica|December 15, 2020
Chronic Nodular Prurigo: A European Cross-sectional Study of Patient Perspectives on Therapeutic Goals and SatisfactionManuel P Pereira, Claudia Zeidler, Joanna Wallengren, et al.Journal of the European Academy of Dermatology and Venereology : JEADV|April 25, 2024
Obesity is linked to disease severity in moderate to severe atopic dermatitis-Data from the prospective observational TREATgermany registryStephan Traidl, Moritz M Hollstein, Nadine Kroeger, et al.Pageof 53